Vertex Pharmaceuticals Inc / Ma
A global biotech developing transformative medicines for serious diseases, Vertex Pharmaceuticals is best known for its cystic fibrosis franchise — KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA, and ALYFTREK — which treats most people with CF in key Western markets. The company also makes CASGEVY, a CRISPR gene-editing therapy for sickle cell disease and beta thalassemia, and JOURNAVX, a non-opioid pain signal inhibitor for acute pain. Its pipeline targets kidney disease, chronic pain, and type 1 diabetes.
Granted 204.2K · Bought 10.0K · Sold 129.7K
Granted 108.4K · Sold 74.2K
Granted 103.8K · Sold 26.4K
Granted 76.9K · Sold 42.3K
Granted 63.1K · Sold 29.2K
Granted 23.6K · Bought 5.0K · Sold 23.6K
Granted 215.6K · Sold 186.2K
Granted 56.7K · Sold 27.5K
Sold 3.8K
Granted 54.0K · Sold 25.0K
Granted 58.1K · Sold 72.3K
Granted 33.4K · Sold 17.1K
Granted 11.8K · Sold 10.0K
Granted 870
Granted 2.6K · Sold 6.3K
Granted 17.4K · Sold 9.6K
Granted 1.8K
Granted 4.7K · Sold 4.1K
Granted 2.7K
Granted 2.2K
Granted 2.5K
Granted 1.8K
Granted 1.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kewalramani ReshmaCEO & President, Director · 47 transactions | -10.9% | 106.0K | 204.2K | 10.0K | 129.7K |
| Sachdev AmitEVP Chief Patient & Ext Af Off · 39 transactions | -0.8% | 65.8K | 108.4K | — | 74.2K |
| Arbuckle Stuart AEVP, COO · 23 transactions | +12% | 63.5Kas of Jul 2025 | 103.8K | — | 26.4K |
| Wagner Charles F JrEVP, CO & FO · 31 transactions | -5.2% | 47.0K | 76.9K | — | 42.3K |
| Tatsis OuraniaEVP, Chief Reg. & Quality Off. · 41 transactions | -3.9% | 46.8K | 63.1K | — | 29.2K |
| Sachs Bruce IDirector · 8 transactions | -12.2% | 45.0Kas of Aug 2025 | 23.6K | 5.0K | 23.6K |
| Leiden Jeffrey MExecutive Chairman, Director · 46 transactions | -1.6% | 35.2K | 215.6K | — | 186.2K |
| Altshuler DavidEVP, Chief Scientific Officer · 30 transactions | +7.6% | 34.5K | 56.7K | — | 27.5K |
| Liu JoyEVP and Chief Legal Officer · 4 transactions | +61.6% | 20.0K | — | — | 3.8K |
| Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · 36 transactions | — | 18.4K | 54.0K | — | 25.0K |
| Bozic CarmenEVP and CMO · 43 transactions | -75.7% | 15.3K | 58.1K | — | 72.3K |
| Biller JonathanEVP and Chief Legal Officer · 29 transactions | +17.9% | 13.7K | 33.4K | — | 17.1K |
| McKechnie DuncanEVP, Chief Commercial Officer · 11 transactions | — | 12.5K | 11.8K | — | 10.0K |
| Garber Alan MDirector · 2 transactions | +13.4% | 7.3K | 870 | — | — |
| Bunnage Mark E.EVP, Chief Scientific Officer · 10 transactions | — | 7.3K | 2.6K | — | 6.3K |
| Ambrose KristenSVP & Chief Accounting Officer · 30 transactions | -3.1% | 6.6K | 17.4K | — | 9.6K |
| Carney LloydDirector · 3 transactions | +18.7% | 6.3K | 1.8K | — | — |
| Bhatia Sangeeta N.Director · 14 transactions | +12.3% | 4.9K | 4.7K | — | 4.1K |
| McKenzie DianaDirector · 6 transactions | +105.9% | 3.4K | 2.7K | — | — |
| Schneider JenniferDirector · 4 transactions | — | 2.2K | 2.2K | — | — |
| Thornberry NancyDirector · 5 transactions | — | 2.1K | 2.5K | — | — |
| Upadhyay SuketuDirector · 5 transactions | -42.8% | 1.6K | 1.8K | — | — |
| Lagarde MichelDirector · 1 transaction | — | 1.1Kas of Oct 2023 | 1.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -672.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.